Context: Epidemiologically, levels of high-density lipoprotein (HDL) cholesterol and its major protein constituent, apolipoprotein A-I (apoA-I), are inversely related to risk of ischemic heart disease (IHD).
P
lasma levels of high-density lipoprotein (HDL) cholesterol and its major protein constituent, apolipoprotein A-I (apoA-I), are inversely related to risk of ischemic heart disease (IHD) in the general population (1) (2) (3) . The suggested protective effect of high levels of HDL cholesterol is mainly believed to be mediated by its involvement in reverse cholesterol transport, i.e. the transport of excess cellular cholesterol from peripheral tissues back to the liver for excretion in the bile (4) . ApoA-I plays a crucial role in HDL particle formation, maturation, and catabolism (5) . Therefore, genetic variation in the APOA1 gene may affect levels of HDL cholesterol and apoA-I as well as risk of IHD and myocardial infarction (MI) in the general population.
Twin and family studies suggest that about 50% of the variance in HDL cholesterol levels in the general popula-tion is attributable to genetic factors (5) . APOA1 is located on chromosome 11q23 and has been widely used as a candidate gene for genotype-phenotype association studies of lipid and lipoprotein levels and risk of cardiovascular disease. In contrast to rare mutations in APOA1 (rare allele frequency Ͻ1%), which are well established causes of familial HDL deficiency syndromes, albeit with unestablished relations to IHD (5, 6) , the study of single-nucleotide polymorphisms (SNPs) (rare allele frequency Ն1%) have yielded varying results (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Thus, it remains to be established whether common genetic variation in APOA1 impacts levels of apoA-I, HDL cholesterol, and risk of IHD and MI in the general population.
We tested the following hypotheses: 1) SNPs in APOA1 affect levels of lipids, lipoproteins, and apolipoproteins in the general population, and 2) SNPs in APOA1 are associated with risk of IHD and MI in the general population to the extent predicted by their effects on apoA-I and HDL cholesterol levels. Consequently, we resequenced the regulatory and coding regions of APOA1 in 190 individuals with the lowest 1% (n ϭ 95) and highest 1% (n ϭ 95) apoA-I levels for age and gender. Next, we genotyped selected genetic variants in all 10,273 individuals in the Copenhagen City Heart Study (CCHS), and in 2361 independently ascertained patients with IHD from the Copenhagen Ischemic Heart Disease Study (CIHDS).
Subjects and Methods

Study cohorts
The Copenhagen City Heart Study
The CCHS is a prospective cardiovascular population study of individuals selected based on the national Danish Civil Registration System to reflect the adult Danish general population aged 20 -80ϩ yr. The study was initiated in 1976 -1978 with follow-up examinations in 1981-1983, 1991-1994, and 2001-2003 (19 
Study designs
Hypothesis 1: SNPs in APOA1 affect levels of lipids, lipoproteins, and apolipoproteins in the general population
To test the first hypothesis, SNPs likely to be functional were genotyped in the entire general population sample (n ϭ 10,273). Possible functionality was suspected if 1) SNPs differed in frequency between high and low apoA-I groups, suggesting a likely effect on levels of apoA-I and HDL cholesterol; 2) SNPs were in or close to a known regulatory promoter site; or 3) SNPs were nonsynonymous. Data from the 1991-1994 and 2001-2003 examinations of the CCHS was used to determine the associations of SNPs on variation in plasma lipid, lipoprotein, and apolipoprotein levels.
Hypothesis 2: SNPs in APOA1 are associated with risk of IHD and MI in the general population
To test our second hypothesis with maximal statistical power, we conducted a case-control study, comprising 4346 cases with IHD from the CCHS and CIHDS and 8288 IHD-free controls from the CCHS. The theoretically predicted risks of IHD and MI, obtained from the CCHS on the basis of apoA-I and HDL cholesterol levels from the 1991-1994 and 2001-2003 examinations, were compared with the actual observed risks from the case-control study.
Laboratory analyses
Gene screening
Genomic DNA was isolated from frozen whole blood (QiaAmp4 DNA blood mini kit; QIAGEN GmbH, Hilden, Germany). Six PCR fragments were amplified covering the APOA1 gene from 827 bp upstream of the ATG translation start site in exon 2 to 193 bp downstream of the stop codon including all four exons of APOA1 and exon-intron boundaries (Supplemental Fig. 1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org). Mutational analysis of the PCR products was performed by denaturing HPLC using a WAVE nucleic acid fragment analysis system (Transgenomic Inc., Omaha, NE). PCR fragments showing heteroduplex formation by denaturing HPLC were subsequently sequenced on an ABI 3730 DNA analyzer (Applied Biosystems Inc., Foster City, CA).
Genotyping
The ABI PRISM 7900HT sequence detection system (Applied Biosystems) was used to genotype the general population sample for two APOA1 SNPs, g.Ϫ560A3 C (tagging the haplotype g.Ϫ560C/g.Ϫ151T/*181G; Supplemental Table 1 ) and g.Ϫ310G3 A. TaqMan-based assays were used. The genotyping failure rate was 0.09%.
Biochemical analyses
Colorimetric and turbidimetric assays were used to measure plasma levels of total cholesterol, HDL cholesterol, triglycerides, and apolipoproteins B and A-I (all Roche Molecular Biochemicals GmbH, Mannheim, Germany). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation (21) or measured directly if triglycerides were 4 mmol/liter or higher.
Other covariates
The risk factors, diabetes mellitus, smoking, and hypertension, were dichotomized and defined as diabetics (self-reported disease, current use of antidiabetic medication, and/or nonfasting plasma glucose Ͼ11.0 mmol/liter), ever-smokers (current smokers and ex-smokers), and hypertensives (current systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg and/or current use of antihypertensive drugs). Body mass index was weight (kilograms) divided by height squared (square meters).
Statistical analyses
We used the statistical software package Stata (version 10.1; StataCorp., College Station, TX). Two-sided P values Ͻ0.05 were considered significant. Categorical and continuous variables were evaluated by Pearson 2 test and by Kruskal-Wallis test with the Mann-Whitney U test as a post hoc test. Cox proportional hazards regression models estimated hazards ratios for IHD and MI as a function of apoA-I and HDL cholesterol levels in the CCHS based on the results of examinations conducted in 1991-1994 and 2001-2004 . In the survival statistics, sex was adjusted for and age was the time scale using left truncation, which implies that age is automatically adjusted for, and therefore not included, as a covariate in the model. The decreases in hazard ratios for IHD and MI for a 1% increase in apoA-I and HDL cholesterol levels in the CCHS were used to predict theoretical hazard ratios for IHD and MI associated with the changes in apoA-I and HDL cholesterol levels caused by the individual genotypes and the combined genotypes; the observed percent increment in plasma apoA-I and HDL cholesterol levels for the individual genotypes and combined genotypes was multiplied with the ␤-coefficients for a hazard ratio for IHD or MI as a function of apoA-I and HDL cholesterol and subsequently transformed into a hazard ratio, as done previously (2, 22, 23) . The theoretically predicted hazard ratios as a function of HDL cholesterol levels were corrected for regression dilution bias (24) . Logistic-regression analysis was used to calculate odds ratios for IHD and MI as a function of genotype adjusted for age and sex in the case-control study (all cases with IHD or MI compared with all control subjects). Genotype combinations were ranked according to increasing HDL cholesterol levels (genotype combinations 1-6) and collapsed into larger groups based on their HDL cholesterol effects (groups 1-2, 3, and 4 -6) to increase power.
Results
Characteristics of participants
Characteristics of subjects with IHD and control subjects in the case-control study are shown in Table 1 . Individuals with IHD were older; had lower HDL cholesterol and apoA-I levels and higher LDL cholesterol, apolipoprotein B, and triglyceride levels; were more obese; and included more hypertensives, smokers, and diabetics, and fewer were women compared with control subjects. Characteristics of individuals in the low apoA-I group, high apoA-I group, and the entire general population sample, the CCHS, are shown in Table 2 . Individuals in the low apoA-I group had lower HDL and total cholesterol levels, higher LDL and triglyceride levels, and were more often smokers and diabetics compared with the high apoA-I group. Individuals in the high apoA-I group were more often hypertensive compared with the low apoA-I group. Values are median, interquartile range, or percentage. Subjects with IHD are from the CCHS and CIHDS, whereas controls are subjects free of IHD in the CCHS. Mann-Whitney U test or Pearson's 2 test was used for continuous and categorical traits, respectively. The risk factors, diabetes mellitus, smoking, and hypertension, were dichotomized and defined as diabetics (self-reported disease, current use of antidiabetic medication, and/or nonfasting plasma glucose Ͼ11.0 mmol/liter), ever-smokers (current smokers and ex-smokers), and hypertensives (current systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg and/or current use of antihypertensive drugs). LDL cholesterol levels were calculated with the Friedewald equation if triglycerides were lower than 4 mmol/liter but measured directly at higher triglyceride levels (21) . a P Ͻ 0.01.
Hypothesis 1: SNPs in APOA1 affect lipids, lipoproteins, and apolipoproteins in the general population
Genetic variation in APOA1
Resequencing of the regulatory and coding regions of APOA1 in individuals from the CCHS with the 1% lowest (n ϭ 95) and 1% highest (n ϭ 95) plasma apoA-I levels identified 13 genetic variants in total (Table 3) . Allele frequencies ranged from 1:380 (0.26%) to 115:380 (30%) in the low and high plasma apoA-I groups (Table 3) . Seven of the 13 genetic variants were SNPs, all noncoding.
Potentially functional SNPs and haplotypes in low and high apoA-I groups
Three of the seven SNPs differed significantly in allele frequency (g.Ϫ560A3 C, P ϭ 0.0004; g.Ϫ151C3 T, P ϭ 0.0008; *181A3 G, P ϭ 0.0008) between individuals with the lowest 1% and highest 1% plasma apoA-I levels (Table 3) . Pairwise linkage disequilibrium pattern for the seven SNPs in APOA1 is shown in Supplemental Fig. 2 . The only SNP pairs with r 2 higher than 0.80, indicating that any one of these SNPs could tag the other two, were g.Ϫ560A3 C/g.Ϫ151C3 T, g.Ϫ560A3 C/*181A3 G, and g.Ϫ151C3 T/*181A3 G. When specific haplotypes were examined, the haplotype with the rare alleles at positions g.Ϫ560A3 C, g.Ϫ151C3 T, and g.*181A3 G was significantly more frequent in the high apoA-I group than in the low apoA-I group (6 vs. 1%, P ϭ 0.002) (Supplemental Table 1 ). Furthermore, a fourth SNP, g.Ϫ310G3 A, was situated 2 bp 3Ј of an important regulatory element (regulatory element B). Finally, there were no nonsynonymous SNPs identified.
Effects of APOA1 SNPs on plasma levels of lipids, lipoproteins, and apolipoproteins
Based on the resequencing results that suggested that the g.Ϫ560C/g.Ϫ151T/*181G haplotype and the g.Ϫ310G3 A SNP might be functional, we genotyped the total general population sample for g.Ϫ560A3 C (tagging the haplotype) and for g.Ϫ310G3 A. The allele frequencies were, respectively, 0.04 and 0. 19 in the CCHS (Table  3) . Genotype frequencies did not differ from those predicted by the Hardy-Weinberg equilibrium.
Lipid, lipoprotein, and apolipoprotein levels in the CCHS for carriers of the two SNPs, g.Ϫ560A3 C and g.Ϫ310G3 A, as well as genotype combinations ordered according to increasing levels of HDL cholesterol are presented in Fig. 1 and compared with noncarriers. The corresponding percent increases in levels of apoA-I and HDL cholesterol as a function of individual genotypes and genotype combinations are given in Figs. 2 and 3 , left columns. In g.Ϫ560A3 C heterozygotes only, apoA-I was increased by 3.9%, and the corresponding increase in HDL cholesterol levels was 4.7%, compared with noncarriers (P values Ͻ0.001). g.Ϫ560A3 C did not affect plasma levels of triglycerides, total cholesterol, LDL cholesterol, or apolipoprotein B. In g.Ϫ310G3 A homozygotes only, plasma levels of apoA-I were increased by 5.1%, and the corresponding increase in HDL cholesterol levels was 7.0%, compared with noncarriers (P values Values are median, interquartile range, or percentage. Low and high apoA-I groups were compared by Mann-Whitney U test or Pearson 2 test. The risk factors, diabetes mellitus, smoking, and hypertension, were dichotomized and defined as diabetics (self-reported disease, current use of antidiabetic medication, and/or nonfasting plasma glucose Ͼ11.0 mmol/liter), ever-smokers (current smokers and ex-smokers), and hypertensives (current systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg and/or current use of antihypertensive drugs). LDL cholesterol levels were calculated with the Friedewald equation if triglycerides were lower than 4 mmol/liter, but measured directly at higher triglyceride levels (21 Allele frequencies are given only for variants with minor allele frequencies greater than 1% (SNPs), whereas only the number of alleles is given for variants with minor allele frequencies of 1% or less (mutation). 
APOA1 SNPs and risk of IHD
To obtain maximal statistical power, we determined the observed odds ratio for IHD and MI as a function of genotype in a case-control study comprising 4346 cases with IHD from the CCHS and CIHDS and 8288 IHD-free controls from the CCHS (Figs. 2 and 3, right panels) . The odds ratios for IHD and MI did not differ significantly from 1.0 for any of the individual genotypes or for genotype combinations (Figs. 2 and 3, right panels) .
Predicted vs. observed risk of IHD
We wanted to address whether SNPs in APOA1 were associated with risk of IHD and MI in the general population to the extent predicted by their effects on apoA-I and HDL cholesterol levels. Consequently, we compared the risk of IHD and MI associated with genetically elevated apoA-I and HDL cholesterol levels with the same decrease in risk of disease as that observed for elevated plasma apoA-I and HDL cholesterol levels encountered in the general population. From the Cox proportional hazards regression models, we estimated that a 1% increase in apoA-I in the CCHS predicted a decrease in risk of 1.5% [hazard ratio ϭ 0.99; 95% confidence interval (CI) ϭ 0.98 -0.99] for IHD, and 2.2% (hazard ratio ϭ 0.98; 95% CI ϭ 0.97-0.99) for MI. Similarly, a 1% increase in HDL cholesterol predicted a decrease in risk of 1.0% (hazard ratio ϭ 0.99; 95% CI ϭ 0.99 -0.99) for IHD and 1.5% (hazard ratio ϭ 0.99; 95% CI ϭ 0.98 -0.99) for MI. Based on these models, we estimated that the maximum increase of 6.6% in apoA-I levels found in compound heterozygotes (genotype 5, ACGA) would predict a decrease in risk of up to 9% (hazard ratio ϭ 0.91; 95% CI ϭ 0.88 -0.93) for IHD (Fig. 2, upper middle panel) and of up to 14% (hazard ratio ϭ 0.86; 95% CI ϭ 0.83-0.90) for MI (Fig.  2, lower middle panel) . We had 100% power to predict the expected reductions in risk of IHD/MI for all apoA-I and HDL cholesterol increases. When collapsing genotypes into larger groups (genotypes 1-2, 3, and 4 -6; Fig. 2, left  panels) , we estimated that the maximum increase in apoA-I levels of 5.6% found in genotype groups 4 -6 would predict a decrease in risk of up to 8% (hazard ratio ϭ 0.92; 95% CI ϭ 0.90 -0.94) for IHD (Fig. 2, upper  middle panel) and of up to 12% (hazard ratio ϭ 0.88; 95% CI ϭ 0.85-0.92) for MI (Fig. 2, lower middle panel) . Correspondingly, we estimated that the 8.5% increase in HDL levels would predict a decrease in risk of up to 8% (hazard ratio ϭ 0.92; 95% CI ϭ 0.90 -0.94) for IHD (Fig. 3, upper  middle panel) and of up to 12% (hazard ratio ϭ 0.88; 95% CI ϭ 0.85-0.91) for MI (Fig. 3, lower middle panel) . When collapsing genotypes into larger groups (genotypes 1-2, 3, and 4 -6; Fig. 3, left panels) , we estimated that the 7.7% increase in HDL cholesterol levels would predict a decrease in risk of up to 7% (hazard ratio ϭ 0.93; 95% CI ϭ 0.91-0.94) for IHD (Fig. 3, upper middle panel) and of up to 11% (hazard ratio ϭ 0.89; 95% CI ϭ 0.86 -0.92) for MI (Fig. 3, lower middle panel) . However, the observed odds ratios for IHD and MI in the case-control study did not differ significantly from 1.0.
Discussion
In this study, we used a systematic approach of resequencing the APOA1 gene in individuals with extreme apoA-I levels to identify genetic variation in APOA1 affecting plasma levels of apoA-I and HDL cholesterol and risk of IHD in the general population. The novel findings include 1) SNPs in APOA1 contribute to increased apoA-I and HDL cholesterol levels in the general population and 2)
FIG. 2.
Effect of APOA1 genotype and genotype combinations on apoA-I levels and theoretically predicted and observed risks of IHD and MI. Differences in plasma levels of apoA-I in the CCHS are shown as a function of APOA1 genotype and combined genotypes as change (percent) with noncarriers as the reference and as mean Ϯ SEM. Theoretically predicted risks of IHD and MI as a function of change in apoA-I levels in the CCHS are shown as hazard ratios as a function of APOA1 genotypes and combined genotypes. Observed risks of IHD and MI in the case-control study as a function of APOA1 genotypes and combined genotypes are shown as odds ratios. Genotype combinations were ranked according to increasing HDL cholesterol levels (genotype combinations 1-6) and collapsed into larger groups based on their HDL cholesterol effects (groups 1-2, 3, andSNPs in APOA1 associated with increases in plasma levels of apoA-I and HDL cholesterol only and do not associate with risk of IHD or MI.
Hypothesis 1: SNPs in APOA1 affect lipids, lipoproteins, and apolipoproteins in the general population
All previously reported SNPs were detected by our resequencing approach (http://www.ncbi.nlm.nih.gov/SNP/; http://www.ensembl.org). In a large Caucasian population, we showed for the first time that two known promoter variants, g.Ϫ560A3 C and g.Ϫ151C3 T, as well as the known 3Ј untranslated region variant, *181A3 G, together constitute a haplotype covering the entire APOA1 gene. A previous study reported a similar linkage disequilibrium pattern for g.Ϫ560A3 C and g.Ϫ151C3 T in Japanese (30); the g.*181A3 G was not genotyped. Furthermore, we determined that the variant form of this haplotype, as well as each genotype considered alone, were overrepresented in the high apoA-I group, suggesting that the genotypes harbored in this specific haplotype affected plasma levels of apoA-I and HDL cholesterol. This was confirmed when genotyping the entire CCHS (n ϭ 10,273); the haplotype (tagged by g.Ϫ560A3 C) was associated with increased plasma levels of both apoA-I and HDL cholesterol regardless of other lipid and lipoprotein levels. This further supports the usefulness of the extreme group strategy for the detection of functionally important variants, as shown previously by us and others (2, 31) . The g.Ϫ151C3 T variant has been   FIG. 3 . Effect of APOA1 genotype and genotype combinations on HDL cholesterol levels and theoretically predicted and observed risks of IHD and MI. Differences in plasma levels of HDL cholesterol in the CCHS are shown as a function of APOA1 genotype and combined genotypes as change (percent) with noncarriers as the reference and as mean Ϯ SE. Theoretically predicted risks of IHD and MI as a function of change in HDL cholesterol in the CCHS are shown as hazard ratios as a function of APOA1 genotypes and combined genotypes. Observed risks of IHD and MI in the case-control study according to APOA1 genotypes and combined genotypes are shown as odds ratios. Genotype combinations were ranked according to increasing HDL cholesterol levels (genotype combinations 1-6) and collapsed into larger groups based on their HDL cholesterol effects (groups 1-2, 3, and 4 -6) to increase power. associated with increased levels of apoA-I or HDL cholesterol (7) (8) (9) (10) or with no change (11) . In agreement with a metaanalysis of earlier studies (n ϭ 3413) (32), we showed that g.Ϫ310G3 A homozygosity associated with increased apoA-I levels in the CCHS. Previous studies have shown increased HDL cholesterol levels (8, 12, 13) or no effect of the g.Ϫ310G3 A SNP (7, 9, 11, 14) . g.Ϫ310G3 A is located close to regulatory element B (28) and a drug-responsive element (33) in the APOA1 promoter, which could be important sites for APOA1 regulation. In vitro studies of this variant have shown decreased expression (34) , increased expression (35) , and no effect on promoter activity (36) . Thus, future studies are needed to reveal the functional effects of the APOA1 g.Ϫ310G3 A variant.
Hypothesis 2: SNPs in APOA1 are associated with risk of IHD and MI in the general population
This is the first study to determine the association between the APOA1 haplotype g.Ϫ560A3 C/g.Ϫ151C3 T/*181A3 G, the g.Ϫ310G3 A SNP, and risk of IHD and MI in a large study of the general population. In this study, the g.Ϫ560A3 C (tagging the haplotype) and the g.Ϫ310G3 A SNPs associated with increases in plasma apoA-I and HDL cholesterol levels of up to 6.6 and 8.5% but did not associate with risk of IHD or MI. This is in accordance with previous studies, which all report either no association with IHD or even increased risk (15) (16) (17) (18) . Different physiological processes that raise HDL cholesterol may have differing effects on coronary disease. For example, the Ϫ480C3 T promoter variant of the hepatic lipase gene (LIPC) increases levels of HDL cholesterol but either increases (37) or has no effect on risk of IHD (22) . Furthermore, clinical trials have shown that cholesteryl ester transfer protein inhibition that raises HDL cholesterol increases coronary disease (38) . Whether this is caused by known side effects of the drug or whether this is due to the perhaps unphysiologically large increase in HDL cholesterol increase itself is not known. Because HDL cholesterol is inversely correlated with risk of IHD in observational studies, it has been assumed for decades that higher apoA-I and HDL cholesterol levels caused a decrease in risk of IHD by promoting reverse cholesterol transport. However, in observational studies, HDL cholesterol also correlates inversely with plasma levels of triglycerides, a marker for the presence of atherogenic remnant lipoproteins. Furthermore, neither candidate gene studies of APOA1 SNPs (15, 18) nor a genome-wide association study (39) has associated APOA1 SNPs with cardiovascular risk. We suggest that the observed atheroprotective effect of high levels of apoA-I and HDL cholesterol in epidemiological studies may not be due to the apoA-I and HDL elevation itself but may be caused by the concomitant reduction in levels of triglycerides and thus in atherogenic remnant lipoproteins (40) .
Limitations
A limitation of our study is that we have studied Caucasians only, and our results may not necessarily apply to other ethnic groups.
We observed an increase in triglycerides for g.Ϫ310GA heterozygotes on a wild-type g.Ϫ560AA background. This finding could potentially confound a real risk reduction associated with an HDL cholesterol increase. However, this is unlikely, because the combined genotype did not affect apoA-I or HDL cholesterol levels. Furthermore, the three combined genotypes that associated with significant increases in both apoA-I and HDL cholesterol had no effects on other lipids and lipoproteins, which potentially could counteract a possible risk reduction.
We observed a higher prevalence of hypertension among subjects with the highest apoA-I and HDL cholesterol compared with those with the lowest levels. A similar association has, to our knowledge, not been reported previously. Because genotypes that associated with increased apoA-I and HDL cholesterol levels did not associate with an increased risk of hypertension, it is unlikely that this is a causal association.
Conclusion
The present systematic screening of APOA1 and subsequent large-scale genotyping of selected, potentially functional SNPs shows that common genetic variation in APOA1 associated with increased apoA-I and HDL cholesterol levels does not associate with decreased risk of IHD or MI in the general population. 
